Precigen (NASDAQ:PGEN) Issues Earnings Results

Precigen (NASDAQ:PGEN) announced its earnings results on Wednesday. The biotechnology company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.02, Zacks reports. The business had revenue of $1.19 million during the quarter, compared to analyst estimates of $1.30 million. Precigen had a negative net margin of 3,521.68% and a negative return on equity of 123.06%.

Precigen Trading Up 0.6 %

Shares of NASDAQ:PGEN opened at $1.80 on Friday. The company has a 50-day moving average price of $1.60 and a 200 day moving average price of $1.15. Precigen has a 12 month low of $0.65 and a 12 month high of $2.17. The company has a market cap of $527.16 million, a price-to-earnings ratio of -3.27 and a beta of 1.58.

Analyst Ratings Changes

PGEN has been the topic of a number of recent research reports. JMP Securities reaffirmed a “market outperform” rating and issued a $5.00 target price on shares of Precigen in a report on Tuesday, January 14th. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of Precigen in a research report on Thursday. Two equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $7.00.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.